Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNX-102 SL in PTSD
NCT05372887Phase 2Withdrawn
- Sponsor
- Tonix Pharmaceuticals
- Start
- Oct 2022
- Primary completion
- Nov 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of Tonmya in post-traumatic stress disorder (PTSD), sponsored by Tonix Pharmaceuticals. Planned start Oct 2022; status: withdrawn.
02
Drugs
Tonmya
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT05372887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05372887.